Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
Gao CA, Weber UM, Peixoto AJ, Weiss SA. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 262. PMID: 31623673, PMCID: PMC6796437, DOI: 10.1186/s40425-019-0748-0.Peer-Reviewed Original ResearchConceptsAutoimmune autonomic ganglionopathyImmune checkpoint inhibitor therapyMetastatic melanomaCheckpoint inhibitorsDual immune checkpoint inhibitionSympathetic nervous system responsesBackgroundImmune checkpoint inhibitorsCardiovascular autonomic testingCheckpoint inhibitor therapyImmune checkpoint inhibitionNervous system responsesEndocrine workupHypotension refractoryAutonomic testingImmunomodulatory therapyAdverse eventsCase presentationAFluid resuscitationInhibitor therapyCheckpoint inhibitionClinical outcomesDisease progressionNew symptomsEndocrine toxicityNivolumabOphthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series
Kim J, Materin MA, Sznol M, Kluger H, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology 2019, 126: 1058-1062. PMID: 30735682, PMCID: PMC6933747, DOI: 10.1016/j.ophtha.2019.01.031.Peer-Reviewed Original Research